XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

 

ARV-110-mCRPC-103

ARV-110 and Abiraterone in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC):  A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer

Local Project Reference:146192
Principal Investigator:Dr. Mark Linch
Drug Class/ Treatment:ARV-110 (Androgen Receptor Proteolysis Targeting Chimera Protein Degrader) + Abiraterone
Patient Population:Metastatic Castration Resistant Prostate Cancer (mCRPC)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

POTENTIA (CBT307-1)

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA)

Local Project Reference:129679
Principal Investigator:Dr. Anuradha Jayaram
Drug Class/ Treatment:CB307 (Trispecific Humabody T-Cell Enhancer)
Patient Population:PSMA+ (IHC) Advanced or Metastatic Solid Tumours
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

 

BAYER 20511

Radium-223 biodistribution study in patients with bone metastatic CRPC:  Open-label, non-randomized Phase 1, multicenter study to assess radium-223 biodistribution in participants with bone metastatic castration resistant prostate cancer (CRPC) receiving radium-223 dichloride treatment.

Local Project Reference:129692
Principal Investigator:Dr. Ursula McGovern
Drug Class/ Treatment:Radium-223 Dichloride (α-emitter Radionuclide)
Patient Population:Bone Metastatic Castration Resistant Prostate Cancer (CRPC)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

DURANCE

DURANCE:  A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr

Local Project Reference:121881
Principal Investigator:Dr. Mark Linch
Drug Class/ Treatment:Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine)
Patient Population:Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ABACUS-2

ABACUS-2:  Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer

Local Project Reference:135538
Principal Investigator:Dr. Mark Linch
Drug Class/ Treatment:Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

EPIC

EPIC Trial:  A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma

Local Project Reference:126549
Principal Investigator:Dr. Constantine Alifrangis
Drug Class/ Treatment:

Cemiplimab (Humanised Monoclonal IgG4 Antibody Targeting PD-1/PD-L1 Pathway)

Monotherapy or Combination with SOC Chemotherapy

Patient Population:

Non-Muscle Invasive Bladder Cancer

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

 

Trials on-hold to recruitment

BXCL701-201

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with mCRPC either Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) or Adenocarcinoma Phenotype

Local Project Reference:113103
Principal Investigator:Dr Mark Linch
Drug Class/ Treatment:BXCL701 (Dipeptidyl Peptidases Inhibitor) Pembrolizumab (PD-1 Monoclonal Antibody)
Patient Population:Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

PRO-MERIT

(Prostate Cancer Messenger RNA Immunotherapy): A first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer.

Local Project Reference:122815
Principal Investigator:Dr Mark Linch
Drug Class/ Treatment:W_pro1 (mRNA Cancer Vaccine)
Patient Population:

Group 1: mCRPC that have exhausted conventional treatment
Group 2: High-risk, Localized Prostate Cancer prior to Prostatectomy

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)